Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update

Brian P. Rubin, Michael C. Heinrich

    Research output: Contribution to journalArticle

    22 Scopus citations

    Abstract

    Gastrointestinal stromal tumors (GISTs) were originally thought to harbor either KIT or platelet-derived growth factor receptor A (PDGFRA) mutations only. However, more recent discoveries have highlighted additional, less common oncogenic driver mutations including NF1, BRAF, and succinate dehydrogenase (SDH) mutations. Genotyping GISTs has become more important since not all genotypes respond equally to FDA-approved tyrosine kinase inhibitors. GIST is a paradigm for personalized cancer therapy. Recent studies demonstrate how immunohistochemistry can be used both to diagnose GIST and to screen for specific mutations. DOG1 is particularly useful in the diagnosis of KIT-negative GIST, including tumors with PDGFRA mutations, which can also potentially be identified by immunohistochemistry for PDGFRA. SDHB immunohistochemistry is useful in characterizing GISTs with SDHA-D mutations, whereas SDHA immunohistochemistry is able to identify SDHA mutant GISTs.

    Original languageEnglish (US)
    Pages (from-to)392-399
    Number of pages8
    JournalSeminars in Diagnostic Pathology
    Volume32
    Issue number5
    DOIs
    StatePublished - Sep 1 2015

    Keywords

    • BRAF
    • GIST
    • KIT
    • NF1
    • Platelet-derived growth factor receptor A
    • Succinate Dehydrogenase

    ASJC Scopus subject areas

    • Pathology and Forensic Medicine

    Fingerprint Dive into the research topics of 'Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update'. Together they form a unique fingerprint.

  • Cite this